US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Novelion Therapeutics Inc

0.6800

0.0000

Volume:- -

Turnover:- -

Market Cap:13.34M

PE:-0.12

High:0.6800

Open:0.6800

Low:0.6800

Close:0.6800

52wk High:2.35

52wk Low:0.5400

Shares:19.62M

Float Shares:12.45M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.6822

EPS(LYR):-5.7584

ROE:162.64%

ROA:-5.36%

PB:-0.15

PE(LYR):-0.12

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Novelion Therapeutics Inc

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.novelion.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases. Its product portfolio includes MYALEPT for the treatment of generalized lipodystrophy; JUXTAPID for treating homozygous familial hypercholesterolemia (HoFH) in adults; and zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company also offers LOJUXTA (lomitapide) hard capsule for the treatment of HoFH in adults; and MYALEPT (metreleptin), a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NVLN/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVLN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVLN\",,,,,undefined,":{"symbol":"NVLN","market":"US","secType":"STK","nameCN":"Novelion Therapeutics Inc","latestPrice":0.68,"timestamp":1570564800000,"preClose":0.68,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":12448376,"shares":19618946,"eps":-5.682162,"marketStatus":"Delisted","change":0,"latestTime":"05-18 06:59:55 EDT","open":0.68,"high":0.68,"low":0.68,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-5.682162,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779111000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.68,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVLN\",,,,,undefined,":{"symbol":"NVLN","floatShares":12448376,"roa":"-5.36%","roe":"162.64%","lyrEps":-5.758398,"shares":19618946,"dividePrice":0,"high":0.68,"amplitude":0,"preClose":0.68,"low":0.68,"week52Low":0.54,"pbRate":"-0.15","week52High":2.35,"institutionHeld":0.3679,"latestPrice":0.68,"eps":-5.682162,"divideRate":0,"volume":0,"delay":0,"ttmEps":-5.682162,"open":0.68},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVLN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-03-14","symbol":"NVLN","fiscalQuarterEnding":"2018/12","expectedEps":-0.9,"name":null,"time":"","type":"earning","dateTimestamp":1552536000000,"reportTimeType":"","actualEps":-1.03},{"market":"US","date":"2018-11-09","symbol":"NVLN","fiscalQuarterEnding":"2018/09","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1541739600000,"reportTimeType":"","actualEps":-1.32},{"market":"US","date":"2018-08-07","symbol":"NVLN","fiscalQuarterEnding":"2018/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1533614400000,"reportTimeType":"","actualEps":-0.64},{"market":"US","date":"2018-05-10","symbol":"NVLN","fiscalQuarterEnding":"2018/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1525924800000,"reportTimeType":"","actualEps":-1.76},{"market":"US","date":"2018-03-15","symbol":"NVLN","fiscalQuarterEnding":"2017/12","expectedEps":-1.58,"name":null,"time":"","type":"earning","dateTimestamp":1521086400000,"reportTimeType":"","actualEps":-1.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVLN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVLN\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.novelion.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases. Its product portfolio includes MYALEPT for the treatment of generalized lipodystrophy; JUXTAPID for treating homozygous familial hypercholesterolemia (HoFH) in adults; and zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company also offers LOJUXTA (lomitapide) hard capsule for the treatment of HoFH in adults; and MYALEPT (metreleptin), a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.","exchange":"NASDAQ","name":"Novelion Therapeutics Inc","nameEN":"Novelion Therapeutics Inc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"NVLN\",market:\"US\",,,undefined,":null}}